Alzheimer's

The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, DC (Feb. 27, 2026) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen Scientist Awards (CSA) acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases.  This year’s award […]

Las Vegas is set to host a significant gathering of Alzheimer’s and Parkinson’s disease research leaders this week, as the Global Alzheimer’s Platform Foundation (GAP) convenes its annual conference from February 25th through February 27th at the Red Rock Casino Resort & Spa. The event will bring together nearly 250 representatives from over 100 clinical […]

The disease currently is diagnosed using expensive scans and lumbar punctures or spinal taps. February 18, 2026 By: Michael Barbella Managing Editor Alzheimer’s disease detection could be quite literally at our fingertips. A major international research project is underway at the U.K. Dementia Research Institute (DRI) to test whether a finger prick-style blood test could be […]

Diagnosing the disease can be expensive, invasive and complicated. Research in RI could help speed up the process Feb. 5, 2026, 5:04 a.m. ETEAST PROVIDENCE – Alzheimer’s, a neurodegenerative disease, is the primary cause of dementia in the United States. In Rhode Island, more than one in 10 adults over age 65 – about 22,000 […]

This Nature article highlights how blood-based biomarkers for Alzheimer’s disease stand to have the potential to transform diagnostics, and how new treatments and therapies are developed. There is mention of how Bio-Hermes-001, and Bio-Hermes-002, use head-to-head comparisons of blood-based biomarkers and digital tests to explore which combinations of blood-based biomarkers perform best across different populations and […]

“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.  A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]

“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]

Tori Rodriguez, MA, LPC, AHC Publish DateJanuary 27, 202 At the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held December 1 to 4, 2025, in San Diego, California, researchers presented new data spanning observational studies, biomarker analyses, and clinical development programs in Alzheimer disease (AD). Key topics included emerging evidence on metabolic therapies such as […]

Alzheimer’s disease study brings new testing to Las Vegas Courtesy Axiom Brain Health’s Kaden Appleberry processes lab sample for study. By Katie Ann McCarver (contact) Monday, January 26, 2026 – 2 a.m. A Las Vegas stronghold in neurology is contributing to a new study spanning multiple states and countries related to the detection and diagnosis of Alzheimer’s disease. Clinical Neurology […]

by News 3 Staff,Updated Fri, January 23, 2026 at 1:20 PM LAS VEGAS (KSNV) — Clinical Neurology Specialists (CNS) in Las Vegas is participating in a groundbreaking international study sponsored by the Global Alzheimer’s Platform Foundation. The Bio-Hermes-002 study seeks volunteers with memory concerns to help identify blood or digital tests that could predict the presence of amyloid […]

Jan 20, 2026 | staff reporterSave for later NEW YORK — UK nonprofit research organization LifeArc said on Monday that it has partnered with the Global Alzheimer’s Platform Foundation (GAP) to evaluate a blood-based test for Alzheimer’s disease. The test is designed to detect three proteins — phosphorylated tau 217, glial fibrillary acidic protein, and neurofilament light […]

Washington D.C., Jan 20, 2026, The Global Alzheimer’s Platform Foundation® (GAP) applauds the House and Senate Committees on appropriations releasing their final bipartisan FY2026 Labor–Health and Human Services–Education appropriations bill which increases funding for Alzheimer’s disease and other dementia research.     “Congress’s bipartisan approval of increased funding for neurodegenerative research sends a powerful message to the millions of […]

The test aims to pick up three proteins known to be associated with Alzheimer’s Jane KirbyMonday 19 January 2026 11:14 GMT Bookmark popover Removed from bookmarksClose popover A pioneering trial has begun to assess whether a simple finger-prick blood test could offer an early diagnosis for Alzheimer’s disease, even before symptoms manifest. Experts are optimistic […]

A major international research project is underway to test whether a finger prick-style blood test could be used to help diagnose Alzheimer’s disease. The trial is looking at three proteins in the blood that are associated with Alzheimer’s and comparing this with the current gold standard approach to diagnosing the disease that uses expensive brain […]

  By Jacquelyn Voghel 01/18/2026 EAST PROVIDENCE – A national research institution’s Rhode Island location is calling for volunteers with Alzheimer’s disease to participate in a study attempting to identify predictive markers of the brain condition. K2 Medical Research – East Providence has begun enrolling participants in the Bio-Hermes 002 Study, an initiative of the Global Alzheimer’s Platform Foundation. The study seeks […]

Spear Bio joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Jan 12, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]

Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]

Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]

20 Dec ‘It’s the best time’: Family members may notice signs of Alzheimer’s at holiday gatherings Posted at 20:23h in Uncategorized by Belinda Russell 0 Comments ATLANTIS, Fla. — It’s the holiday season and while you celebrate with friends and family some experts say you may also notice some changes in elderly loved ones you haven’t seen for a while. Dr. Linda […]

Aging Emerging biomarkers and digital tools are unlocking earlier and more accurate diagnosis Teresa, 75, an Alzheimer’s patient and former businesswoman, poses for a photograph inside the Alzheimer Foundation, in Mexico City, Mexico, on April 19, 2012.REUTERS/Edgard Garrido by Lydia Wu, Jennifer Panlilio, Melissa Lee, Laura Nisenbaum, Aishu Sukumar December 10, 2025 Alzheimer’s disease and related dementias affect more than […]

The Global Alzheimer’s Platform Foundation® (GAP) today issued a statement following the release of top-line updates from two Alzheimer’s clinical trials: Recently, developments in two important Alzheimer’s clinical research studies were reported. The two studies were: Novo Nordisk’s Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide, and Johnson & Johnson’s Phase 2b trial evaluating the […]

About This Episode The quest to speed up clinical trials is personal for John Dwyer, CEO of the Global Alzheimer’s Platform (GAP). A long-time UsA2 advocate, he’s been motivated by the generations of family members lost to Alzheimer’s and Parkinson’s disease. Dwyer shares with BrainStorm host Meryl Comer the critical challenges of NIH funding cuts […]

November 19, 2025 Delivers Life-Changing Early Detection for 580,000 Floridians Living with Alzheimer’s WASHINGTON — Today, Congressman Vern Buchanan, Vice Chairman of the House Ways and Means Committee and Chair of the Health Subcommittee, announced the introduction of the Alzheimer’s Screening and Prevention (ASAP) Act alongside Congressman Paul Tonko (D-N.Y.). Senators Susan Collins (R-Maine) and Catherine Cortez Masto (D-Nev.) introduced companion legislation in the Senate. This bipartisan, bicameral […]

Last week, the Global Alzheimer’s Platform Foundation’s (GAP) Inclusive Research Initiative (IRI) team hosted its second annual virtual conference focused on improving Alzheimer’s and dementia research by increasing diversity among participants in neurodegenerative clinical trials. We are proud to have created a platform for meaningful dialogue and hope it has inspired new ideas, collaborations, and opportunities for those […]